What is Sartorius Aktiengesellschaft?
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide.
SUVPF · Verdict
Limited reward · elevated risk
SUVPF has limited near-term tailwinds — volatility and valuation weigh on the model output.
Based on 88% data coverage
SUVPF · Verdict
Weak vs peers
P/E 40.3× · PEG 0.97
Interest covered 3.3×
Rev -5.4% CAGR · earnings -38.9%
4% net margin · 6% ROE
Model-based scoring. For information only — not financial advice.
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 18.68B, and a P/E ratio of 102.1x.
The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.